Venetoclax
Venclexta · BCL2i · BCL-2
Selective BCL-2 inhibitor. Restores apoptosis in cancer cells that overexpress BCL-2. Used in combination with BTK inhibitors in MCL.
Used in combination regimens for R/R MCL (not FDA-approved specifically for MCL)
Constantine Tam
Professor, Director of Haematology · Peter MacCallum Cancer Centre / St Vincent's Hospital / University of Melbourne
Preetesh Jain
Assistant Professor, Department of Lymphoma and Myeloma · MD Anderson Cancer Center
Toby Eyre
Consultant Haematologist · University of Oxford / Oxford University Hospitals
Wojciech Jurczak
Professor, Head of Clinical Oncology Department · Maria Sklodowska-Curie National Research Institute of Oncology
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.
Cancer · Apr 2026
[Rapid determination of venetoclax in plasma by ultra performance liquid chromatography-tandem mass spectrometry].
Se pu = Chinese journal of chromatography · Mar 2026
Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.
Blood advances · Jan 2026
Emerging first-line treatment approaches for mantle cell lymphoma.
Leukemia & lymphoma · Jan 2026
SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma.
Blood advances · Dec 2025
BCL-2 inhibition in Waldenström macroglobulinaemia and marginal zone lymphoma.
British journal of haematology · Dec 2025
Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
International journal of clinical oncology · Nov 2025
Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Leukemia & lymphoma · Oct 2025
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study.
The Lancet. Haematology · Oct 2025
Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma.
Blood advances · Sep 2025
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment.
BMC cancer · Aug 2025
Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy.
The Journal of pathology · Aug 2025
The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas.
British journal of haematology · Jun 2025
Ibrutinib plus venetoclax improves progression-free survival in refractory or relapsed mantle cell lymphoma.
Cancer · Jun 2025
A Triple Oral Combination of Bendamustine, Acalabrutinib, and Venetoclax Demonstrates Efficacy Against Mantle Cell Lymphoma In Vitro and In Vivo.
Cancers · Jun 2025
Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma.
Annals of hematology · Apr 2025
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
The Lancet. Oncology · Feb 2025
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.
Blood · Jan 2025
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia.
Blood · Dec 2024
Ibrutinib and venetoclax combination therapy for mantle cell lymphoma: are two better than one?
Expert review of hematology · Dec 2024